Genomenon Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 37
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 21

Genomenon General Information

Description

Developer of a genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists to treat cancer and other inheritable diseases, enabling physicians to improve patients outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • 3135 South State Street
  • Suite 350 BR
  • Ann Arbor, MI 48108
  • United States
+1 (734) 000-0000

Genomenon Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Genomenon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private 01-Aug-2021 000.00 Completed Generating Revenue
11. Later Stage VC 16-Mar-2021 00.00 000.00 Completed Generating Revenue
10. Debt - PPP 07-Apr-2020 00.000 Completed Generating Revenue
9. Early Stage VC 08-Jan-2019 00.00 00.000 Completed Generating Revenue
8. Early Stage VC (Series A) 07-Jul-2018 00.000 00.000 00.000 Completed Generating Revenue
7. Grant 25-Apr-2017 00.00 00.000 Completed Generating Revenue
6. Seed Round 31-Aug-2016 00.00 00.000 00.000 Completed Generating Revenue
5. Seed Round 07-Jan-2016 00000 00.000 Completed Generating Revenue
4. Grant 06-Nov-2015 $100K $1.68M Completed Generating Revenue
3. Angel (individual) 01-Nov-2015 $750K $1.68M Completed Generating Revenue
To view Genomenon’s complete valuation and funding history, request access »

Genomenon Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 1 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Genomenon’s complete cap table history, request access »

Genomenon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a genome interpretation software designed to improve cancer diagnosis and treatment. The company's software
Discovery Tools (Healthcare)
Ann Arbor, MI
37 As of 2021
000.00
00000000000 000.00

0000 000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
000000000 00000 (0000000000)
Toronto, Canada
00 As of 0000
00000
00000000000 00000

000000 0

odo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia
00000 0000000000 0000000000 0000000
Seattle, WA
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genomenon Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Deep Genomics Venture Capital-Backed Toronto, Canada 00 00000 00000000000 00000
000000 00000000 Venture Capital-Backed Seattle, WA 00 00.000 0000000000 0 00.000
00000000 000000 00 Venture Capital-Backed Baltimore, MD 000 00000 00000000000 00000
000000 Venture Capital-Backed Palo Alto, CA 00 0000 00000000000 0000
000000 00000000 Formerly VC-backed Saint Sulpice, Switzerland 000 00000 000000000 00000
You’re viewing 5 of 25 competitors. Get the full list »

Genomenon Executive Team (9)

Name Title Board Seat Contact Info
Michael Klein Chief Executive Officer & Board Member
Steve Schwartz Co-Founder & Chief Technology Officer
Steve Schwartz Co-Founder & Chief Technology Officer
Mark Kiel Ph.D Co-Founder, President, Chief Scientific Officer & Board Member
Lianna Cecil Senior Controller
You’re viewing 5 of 9 executive team members. Get the full list »

Genomenon Board Members (7)

Name Representing Role Since
Charlie Moret Invest Michigan Board Member 000 0000
David Gregorka Invest Michigan Board Member 000 0000
Mark Kiel Ph.D Genomenon Co-Founder, President, Chief Scientific Officer & Board Member 000 0000
Michael Klein Genomenon Chief Executive Officer & Board Member 000 0000
Patricia Glaza Invest Detroit Ventures Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Genomenon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genomenon Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BroadOak Capital Partners Growth/Expansion Minority 000 0000 000000 0
Green Park & Golf Ventures Venture Capital Minority 000 0000 000000 0
Michigan Rise Venture Capital Minority 000 0000 000000 0
Red Cedar Ventures Venture Capital Minority 000 0000 000000 0
Atain Insurance Companies Corporation Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »